In this work 50 cases of ovarian tumors were studiedHistopathologicallyImmunohistochemically for C-erbB-2 expressionFlow cytometric study for DNA ploidy and S-phase fractionFrom our study we conclude the following:1- There is extensive expression of C-erbB-2 in epithelial ovarian tumors and it is overexpressed in ovarian carcinoma.2- The expression of C-erbB-2 in borderline tumors tend to be like that of benign tumors, so these lesions are in fact benign and better classified as proliferative except in the minority they turn frankly malignant.Renal involvement in children with malignanciesAbstract Renal complications in children with malignancies primarily arise from renal parenchymal tumors,tumor lysis syndrome, and malignant infilteration or obstruction of the urinary tract. Therapy-associated renal side effects may develop following surgical and cytostatic treatment or be induced by radiotherapy. Clinically, both acute renal failures, for example following cisplatin, or chronic dysfunction, following ifosfamide and resulting in growth failure, are observed. Frequencies of renal impairment in these patients are not well established, but terminal renal failure is a rare event. Pediatric malignancies account for only 0.9% of patients on renal replacement therapy; the majority of these patients had been treated for a bilateral nephroblastoma. Since potentially serious long term renal sequelae may evolve following both single measures and additive nephrotoxic effects, long term monitoring of growth, blood pressure, and renal function is mandatory for a great proportion of former pediatric oncology patients.Polly E. KintzelAnticancer Drug-Induced Kidney DisordersAbstractChemotherapy can cause nephrotoxicity, and renal impairment can results in altered excretion and metabolism of chemotherapeutic agents. Renal dysfunction is a problematic adverse effect that can hinder continued administration of anticancer treatment, in addition to impending the optimal use of ancillary and supportive medications and measures.Mechanisms of chemotherapy-induced renal dysfunction generally include damage to vascular or structures of the kidneys, hemolytic uremic syndrome and prerenal perfusion deficits. Patients with cancer are frequently at risk of renal impairment secondary to disease-related and iatrogenic causes). Cisplatin and carboplatin cause dose-related renal dysfunction. In addition to elevation of serum creatinine levels and uremia, electrolyte abnormalities, such as hypomagnesemia and hypokalemia, are well known adverse effects of cisplatin. Methotrexate can cause elevation of serum creatinine levels, uremia and haematuria. Acute renal failure is reported after high dose methotrexate therapy. Urinary alkalinization and hydration confer protection against methotrexate-induced renal dysfunction. Dose- and age-related proximal tubular damage is an adverse effect of ifosfamide. In addition to renal wasting of electrolytes, glucose and amino acids, Fanconi syndrome and rickets after ifosfamide administration have been reported in the literature. Hemolytic uremia is a rare but serious adverse effect of gemcitabine .AbstractRainer Rossi – Robert Kleta – Jochen H.H. EhrichRenal involvement in children with malignanciesAbstract Renal complications in children with malignancies primarily arise from renal parenchymal tumors,tumor lysis syndrome, and malignant infilteration or obstruction of the urinary tract. Therapy-associated renal side effects may develop following surgical and cytostatic treatment or be induced by radiotherapy. Clinically, both acute renal failures, for example following cisplatin, or chronic dysfunction, following ifosfamide and resulting in growth failure, are observed. Frequencies of renal impairment in these patients are not well established, but terminal renal failure is a rare event. Pediatric malignancies account for only 0.9% of patients on renal replacement therapy; the majority of these patients had been treated for a bilateral nephroblastoma. Since potentially serious long term renal sequelae may evolve following both single measures and additive nephrotoxic effects, long term monitoring of growth, blood pressure, and renal function is mandatory for a great proportion of former pediatric oncology patients.Polly E. KintzelAnticancer Drug-Induced Kidney DisordersAbstractChemotherapy can cause nephrotoxicity, and renal impairment can results in altered excretion and metabolism of chemotherapeutic agents. Renal dysfunction is a problematic adverse effect that can hinder continued administration of anticancer treatment, in addition to impending the optimal use of ancillary and supportive medications and measures.Mechanisms of chemotherapy-induced renal dysfunction generally include damage to vascular or structures of the kidneys, hemolytic uremic syndrome and prerenal perfusion deficits. Patients with cancer are frequently at risk of renal impairment secondary to disease-related and iatrogenic causes). Cisplatin and carboplatin cause dose-related renal dysfunction. In addition to elevation of serum creatinine levels and uremia, electrolyte abnormalities, such as hypomagnesemia and hypokalemia, are well known adverse effects of cisplatin. Methotrexate can cause elevation of serum creatinine levels, uremia and haematuria. Acute renal failure is reported after high dose methotrexate therapy. Urinary alkalinization and hydration confer protection against methotrexate-induced renal dysfunction. Dose- and age-related proximal tubular damage is an adverse effect of ifosfamide. In addition to renal wasting of electrolytes, glucose and amino acids, Fanconi syndrome and rickets after ifosfamide administration have been reported in the literature. Hemolytic uremia is a rare but serious adverse effect of gemcitabine .AbstractRainer Rossi – Robert Kleta – Jochen H.H. EhrichRenal involvement in children with malignanciesAbstract Renal complications in children with malignancies primarily arise from renal parenchymal tumors,tumor lysis syndrome, and malignant infilteration or obstruction of the urinary tract. Therapy-associated renal side effects may develop following surgical and cytostatic treatment or be induced by radiotherapy. Clinically, both acute renal failures, for example following cisplatin, or chronic dysfunction, following ifosfamide and resulting in growth failure, are observed. Frequencies of renal impairment in these patients are not well established, but terminal renal failure is a rare event. Pediatric malignancies account for only 0.9% of patients on renal replacement therapy; the majority of these patients had been treated for a bilateral nephroblastoma. Since potentially serious long term renal sequelae may evolve following both single measures and additive nephrotoxic effects, long term monitoring of growth, blood pressure, and renal function is mandatory for a great proportion of former pediatric oncology patients.Polly E. KintzelAnticancer Drug-Induced Kidney DisordersAbstractChemotherapy can cause nephrotoxicity, and renal impairment can results in altered excretion and metabolism of chemotherapeutic agents. Renal dysfunction is a problematic adverse effect that can hinder continued administration of anticancer treatment, in addition to impending the optimal use of ancillary and supportive medications and measures.Mechanisms of chemotherapy-induced renal dysfunction generally include damage to vascular or structures of the kidneys, hemolytic uremic syndrome and prerenal perfusion deficits. Patients with cancer are frequently at risk of renal impairment secondary to disease-related and iatrogenic causes). Cisplatin and carboplatin cause dose-related renal dysfunction. In addition to elevation of serum creatinine levels and uremia, electrolyte abnormalities, such as hypomagnesemia and hypokalemia, are well known adverse effects of cisplatin. Methotrexate can cause elevation of serum creatinine levels, uremia and haematuria. Acute renal failure is reported after high dose methotrexate therapy. Urinary alkalinization and hydration confer protection against methotrexate-induced renal dysfunction. Dose- and age-related proximal tubular damage is an adverse effect of ifosfamide. In addition to renal wasting of electrolytes, glucose and amino acids, Fanconi syndrome and rickets after ifosfamide administration have been reported in the literature. Hemolytic uremia is a rare but serious adverse effect of gemcitabine .